Perceptions of combination nicotine replacement therapy and vaporised nicotine product use for tobacco smoking cessation following discharge from alcohol and other drug residential withdrawal services: A qualitative analysis

JOSHUA TRIGG1, JANE RICH2, EDWINA WILLIAMS2, AMANDA BAKER2, NATALIE WALKER3, MARK DAGLISH4, CHRIS BULLEN3, NADINE EZARD5,∗, BILLIE BONEVSKI1

1Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, South Australia, Australia 2School of Medicine and Public Health, College of Medicine, Health and Wellbeing, University of Newcastle, NSW, Australia 3The National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand. 4Faculty of Medicine, University of Queensland, and Royal Brisbane and Women's Hospital, Queensland, Australia. 5Alcohol and Drug Service, St Vincent’s Hospital Sydney, Australia. 6Faculty of Medicine, University of New South Wales, NSW, Australia

Presenter email: joshua.trigg@flinders.edu.au

Introduction and aims: Tobacco smoking is highly prevalent among alcohol and other drug (AOD) service clients in Australia (77%). Despite clients’ interest in quitting smoking and nicotine replacement therapy, abstinence is infrequently sustained post-discharge. Vaporised nicotine products (VNP) are an alternative means of managing nicotine withdrawal after discharge from residential smoke-free clinical sites, which we are currently trialling. This study examined AOD service clients’ experiences of combination nicotine replacement therapy (C-NRT) or VNP for smoking cessation post-discharge.

Method/approach: We interviewed a subset (n=31) of residential service users from the NEAT clinical trial (n=367), who used 12-week C-NRT or VNP with Quitline access for smoking abstinence post-discharge from a residential AOD withdrawal service. Participants aged ≥18 years who smoked tobacco and had not used a VNP in the past month described their health and social changes, tobacco cravings, nicotine use, Quitline experience, and barriers and facilitators to C-NRT or VNP for smoking cessation. We inductively analysed interview transcripts for salient themes.

Key Findings: C-NRT and VNP were feasible and acceptable for smoking cessation. C-NRT was useful for managing nicotine cravings, with inhalators having potential to address smoking behaviour. VNP use was viewed as effective for smoking cessation and managing cravings post-discharge, with some drawbacks for VNP (e.g., taste) and C-NRT (e.g., behavioural preferences). Quitline services received mixed support, as participants could access support via AOD counselling.

Discussions and Conclusions: Using C-NRT and VNPs for smoking cessation was considered generally acceptable by AOD service clients. Accessing suitable nicotine products for VNP use beyond the trial was a barrier to sustained abstinence.

Implications for Practice or Policy: Addressing experiential aspects of C-NRT and VNP use can inform services’ support for smoking cessation approaches based on client suitability.

Disclosure of Interest Statement: Authors declare no conflicts of interest. Work was NHMRC funded (GNT1160245).